Third time the charm for Alzheimer's drug?

Share this article:

Eli Lilly's experimental Alzheimer's treatment was ruled a failure in two earlier trials. But when investigators combined solanezumab's data from both tests, they discovered that cognitive declines were slowed by 34% among patients who started out with mild symptoms. Based on those results, solanezumab has been selected for a federally sponsored study for people who have not yet suffered significant memory loss. Brigham and Women's Hospital is helping coordinate the three-year investigation, which could cost up to $100 million."This is the first time investigators will test an amyloid-clearing drug in older individuals thought to be in the pre-symptomatic stage of Alzheimer's disease," the hospital announced. They are hoping the medication will reduce memory decline by 30%.

Share this article:

More in Products

LINK Innovation Competition crowns Walalight best

The Walalight™ system, which simulates natural sunlight exposure and promotes regular circadian rhythms, won first place at the 2014 LINK Innovation Competition on Monday in Chicago.

Nestlé Professional MINOR adds low-sodium, gluten-free base

Nestlé Professional MINOR adds low-sodium, gluten-free base

MINOR's Low Sodium Gluten Free Base is available in chicken, beef and vegetable, Nestle Professional announced.

Larson Electronics debuts mobile power distribution system

Larson Electronics debuts mobile power distribution system

The Larson Electronics MDC-240-100MB-8X120 temporary power distribution system is now available for those who need to use power sources independently of a work area.